GlaxoSmithKline 176 Share capital Nature of trading market Glaxo Wellcome The Ordinary Shares of the company were listed on the London Fiscal period from 1st January to 26th December 2000 Stock Exchange on 27th December 2000.
The shares were also Pence per share listed on the New York Stock Exchange in the form of American High Low Depositary Shares ADSs from the same date.
2000 2110 1440 The following table sets out, for the periods indicated, the high and low middle market closing quotations in pence for the shares Fiscal period on the London Stock Exchange, as derived from its Daily Official from 1st January to 26th December 2000 US dollars per ADS List, and the high and low last reported sales prices in US dollars for the ADSs on the New York Stock Exchange, as derived from High Low the New York Stock Exchange Composite Tape.
3 2000 63 4 46 Information relating to the share and ADS prices for Glaxo Wellcome and SmithKline Beecham prior to the date of SmithKline Beecham the merger is also given.
At 25th February 2005, the number of holders of record of shares in the USA was 1,187 with holdings of 1,776,334 shares, and the number of registered holders of the ADRs was 44,537 with holdings of 401,140,809 ADRs.
Certain of these shares and ADRs were held by brokers or other nominees, as a result the number of holders of record or registered holders in the USA is not representative of the number of beneficial holders or of the residence of beneficial holders.
Control of company As far as is known to the company, it is not directly or indirectly owned or controlled by one or more corporations or by any government.
The company does not know of any arrangements, the operation of which might result in a change in control of the company.
Substantial shareholdings At 25th February 2005, the company had received notification of the following interests of three per cent or more in the shares in issue, excluding Treasury shares: BNY Nominees Limited holds 802,281,619 shares representing 13.68 per cent.
These shares are held on behalf of holders of ADRs, which evidence ADSs.
Legal & General Investment Management Limited holds 215,495,981 shares representing 3.67 per cent.
Barclays plc holds 229,512,017 shares representing 3.91 per cent.
As far as is known to the company, no other person was the owner of three per cent or more of the shares in issue, excluding Treasury shares of the company.
Directors and Officers The interests of the Directors and Officers of the company, as defined in the Companies Act 1985, in share options of the company are given in the Remuneration Report pages 43 to 58.
Exchange controls and other limitations affecting security holders There are currently no UK laws, decrees or regulations restricting the import or export of capital or affecting the remittance of dividends or other payments to holders of the companys shares who are non-residents of the UK.
There are no limitations relating only to non-residents of the UK under English law or the companys Memorandum and Articles of Association on the right to be a holder of, and to vote in respect of, the companys shares.
Documents on display The Memorandum and Articles of Association of the company and other documents referred to in this Annual Report are available for inspection at the Registered Office of the company.
Publications This year GlaxoSmithKline is again producing a Corporate Responsibility Report covering performance in areas including community investment, business ethics and integrity, access to medicines, R&D and environmental health and safety.
The report will be published on the website at the end of March.
